Pakistani and Chinese enterprises concluded over 120 Memorandums of Understanding, joint ventures, and commercial agreements with a cumulative value exceeding 1.7 billion dollars during the 6th Pakistan-China Business to Business Investment Conference on Pharmaceuticals, Biotechnology and Healthcare. The landmark gathering brought together corporate executives, research leaders, and government authorities from both nations to expand commercial linkages and deepen industrial cooperation across the life sciences sector.
Pakistan Ambassador to China Khalil Hashmi announced the official outcome of the two-day event on social media platform X, confirming the successful completion of bilateral negotiations and project signings. The summit served as a dedicated operational platform to translate long-standing diplomatic goodwill into tangible corporate deals, cross-border equity participation, and shared industrial capacity.
According to details provided by the ambassador, the newly executed agreements span a comprehensive set of sub-sectors within the healthcare ecosystem. These include biotechnology research, human vaccine manufacturing, biological products, active pharmaceutical ingredients synthesis, medical equipment production, commercial pharmaceutical formulation, Traditional Chinese Medicine, and clinical trial management. The broad scope reflects a strategic transition toward domestic manufacturing of specialized life-saving therapeutics and high-value medical hardware.
The conference was organized as a coordinated initiative by the Embassy of Pakistan in Beijing alongside its four regional consulates in China. The project received direct executive direction and support from Prime Minister Shehbaz Sharif, Deputy Prime Minister and Foreign Minister Ishaq Dar, the Minister for National Health, and the Adviser to the Prime Minister on Industries.
A broad spectrum of state institutions and regulatory authorities collaborated to structure the two-day proceedings and facilitate commercial discussions. Key participating bodies included the Ministry of National Health Services, Regulations and Coordination, the Drug Regulatory Authority of Pakistan, the Trade Development Authority of Pakistan, the Board of Investment, and the Special Investment Facilitation Council. Representatives from across the domestic and international private sectors participated in structured matchmaking sessions to assess licensing frameworks and operational opportunities.
Ambassador Hashmi emphasized that the conference has established a firmer foundation for economic integration between the healthcare industries of both countries. By facilitating direct interactions between factory operators, research institutions, and financiers, the initiative creates concrete pathways for technology transfers and local value addition within domestic supply chains.
Moving forward, institutional teams from both sides will launch immediate follow-up actions to convert non-binding memorandums into legally enforceable contracts and operational joint ventures. Diplomatic officials noted that the primary goal of the coming phase is to convert signed investment commitments into actual ground-level production units, active chemical synthesis plants, specialized clinical facilities, and long-term corporate projects operating within Pakistan.
Follow the PakBanker Whatsapp Channel for updates across Pakistan’s banking ecosystem.